In recent years, glucagon-like peptide-1-based (GLP-1-based) treatments such as Ozempic or Wegovy have shown promise in tackling diseases such as diabetes and obesity, but they can also cause side effects.
As a 2025 Schmidt Science Fellow, Ren Hao seeks to understand how GLP-1 is naturally secreted upon exposure to mechanical stimuli. Using this knowledge, Ren Hao will develop medical devices that exploit mechanical stimuli to modulate GLP-1 production in the human body.
Ren Hao’s research aims to offer patients a less invasive treatment option with fewer side effects.
Ren Hao will pivot from Mechanical Engineering to Biomedical Sciences